Tirzepatide for Management of Weight Loss and Sleep Apnea

Exploring the Potential of Tirzepatide in Addressing Obstructive Sleep Apnea Secondary to Obesity

Obstructive sleep apnea (OSA) is a sleep disorder that impacts millions globally. In the United States alone, it is estimated that approximately 39 million adult Americans suffer from sleep apnea, with many cases undiagnosed. Men are more likely to have this condition than women, reflecting differences in fat distribution, airway anatomy, and hormone profiles that influence sleep and breathing patterns.

Understanding Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is characterized by repeated stopping and starting of respirations during sleep. These interruptions, known as apneas, occur due to the partial or complete collapse of the airway and last for several seconds to minutes. Signs and symptoms of OSA include loud snoring, abrupt awakenings accompanied by gasping or choking, morning headache, daytime sleepiness, difficulty concentrating, mood changes, and high blood pressure.

Obesity, particularly excess body weight around the neck area, which exacerbates airway collapse, is a major factor in the development and exacerbation of sleep apnea. Disruption in breathing occurs when fatty tissues obstruct the airway during sleep, causing decreased oxygen distribution to major organs such as the brain, heart, and liver. The link between weight loss and sleep apnea underscores the importance of addressing contributing factors to mitigate these health risks.

Mounjaro/Zepbound Injection: Weight Loss Rx Shortage Affecting Patients

Mounjaro and Zepbound, primarily used for managing type 2 diabetes has emerged due to their notable side effects of significant weight loss. As social media has spread the news quickly, demand has skyrocketed, leaving many patients searching for alternatives.

With the key active ingredient being Tirzepatide, the compounded medication has emerged as a beacon of hope, especially since it can be custom-compounded on-demand by skilled pharmacists at compounding pharmacies like HDRx, a trusted name in the field.

The overwhelming demand for Tirzepatide following its viral rise has led to a supply shortage, prompting both patients and healthcare providers to seek reliable alternatives. HDRx stands ready to provide quality, compounded Tirzepatide during these challenging times.


What is Tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means it targets areas in the body that affect glucose metabolism and appetite regulation which leads to significant weight loss, offering hope for patients with obesity-induced obstructive sleep apnea.


What is the Research is Saying?

Tirzepatide has shown potential in reducing the severity of sleep apnea by promoting significant weight loss and enhancing metabolic parameters. Its effects extend beyond glucose control and include substantial reductions in body weight, which can directly impact the structural causes of sleep apnea related to obesity and ultimately result in the individual’s improved physical and psychosocial well-being.

Read more: Tirzepatide for the Treatment of Obstructive Sleep Apnea: Rationale, Design, and Sample Baseline Characteristics


In another study,

“Participants with OSA and obesity or overweight treated with tirzepatide had significantly greater weight reduction than those treated with placebo in the SURMOUNT-1 trial. This degree of weight loss would be expected to have a clinically meaningful impact on OSA severity and is being investigated in the SURMOUNT-OSA trial.”

Read more: Effect of Tirzepatide on Weight Loss in Patients with Obstructive Sleep Apnea and Obesity


A striking outcome from another recent study revealed that

“40% of participants who used Tirzepatide for 68 weeks experienced a weight loss of 20% or more of their initial body weight—comparable to results typically seen with sleeve gastrectomy”

This discovery positions Tirzepatide as a potential non-surgical alternative for significant weight management.

Source: The Journal of the American Medical Association (JAMA)

HDRx Tirzepatide Injection Sublingual Compounding Pharmacy GLP-1 Medications Michigan Prescription Rx

Availability at Health Dimensions Clinical Pharmacy

Addressing weight loss and sleep apnea concurrently can be crucial for overall health and well-being. Health Dimensions Clinical Pharmacy provides easy access to tirzepatide, among other medications (with prescription), for those seeking weight management options. We are dedicated to offering innovative health solutions focusing on personalized care. Whether you’re dealing with obstructive sleep apnea or other health challenges, our team is here to assist you in your health journey.

We understand the complexities of managing sleep apnea and are committed to providing the resources and support needed to improve your quality of life. Contact us now and explore how tirzepatide and other therapies can fit into your health regimen.

Are you an ENT Provider? Let’s work together to provide options for your Obstructive Sleep Apnea (OSA) patients. We work with hand-in-hand with ENT practitioners and patients for customized approaches through compounded medications.

HDRx offers compounded Tirzepatide to patients in multiple states.

Prescription required. HDRx is licensed to ship prescriptions to MI, OH, IN, IL, IN, WI, MN.





American Medical Association. (2022, April 01). What Doctors Wish Patients Knew About Sleep Apnea. https://www.ama-assn.org/delivering-care/public-health/what-doctors-wish-patients-knew-about-sleep-apnea

Bonsignore, M. R., Baiamonte, P., Mazzuca, E., Castrogiovanni, A., & Marrone, O. (2019). Obstructive sleep apnea and comorbidities: a dangerous liaison. Multidisciplinary respiratory medicine, 14, 1-12.

Grunstein, R. R., Taylor, R., Shinde, S., Dunn, J. P., Bednarik, J., Stefanski, A., & Falcon, B. (2024). 0620 Effect of Tirzepatide on Weight Loss in Patients with Obstructive Sleep Apnea and Obesity from SURMOUNT-1. Sleep, 47(Supplement_1), A264-A265.

Malhotra A, Bednarik J, Chakladar S, Dunn JP, Weaver T, Grunstein R, Fietze I, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Bunck MC. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial. Contemp Clin Trials. 2024 Mar 26;141:107516. doi: 10.1016/j.cct.2024.107516. Epub ahead of print. PMID: 38547961.

National Council on Aging. (2023, October 04). Sleep Apnea Statistics and Facts You Should Know. https://www.ncoa.org/adviser/sleep/sleep-apnea-statistics/
Romero-Corral, A., Caples, S. M., Lopez-Jimenez, F., & Somers, V. K. (2010). Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest, 137(3), 711-719.

MPA logo - health dimensions clinical pharmacy is michigan pharmacists association member
PCAB Logo - HDRX is an Accredited Compounding Pharmacy
HDRX is an Alliance for Pharmacy Compounding member - logo
PCCA - Health Dimensions Clinical Pharmacy is a PCCA member
Health Dimensions is an APMS member
Pharmacy Compounding Accreditation Board - Logo
podiatry and compounding

How Podiatrists Work with Compounding Pharmacists

Regardless of the medications involved, the close partnership between a podiatrist and a compounding pharmacy provides ...

This is a Text Box


This is a CTA

Test box with CTA


This is a blurb

This is text on a blurb

Skip to content